Editorial Commentary Simultaneous targeting of MET overexpression in EGFR mutation-positive non-small cell lung cancer can increase the benefit of EGFR-TKI therapy? Hiroaki Kanemura, Masayuki Takeda, Kazuhiko Nakagawa
